According to guidelines from the American Academy of Neurology (AAN), which were published in 2018, when patients with MS are stable (no relapses, no disability progression, stable imaging), continuation of their current DMT is recommended unless the patient and physician jointly decide to initiate a trial off therapy. When stopping treatment, joint guidelines from the European Committee For Treatment And Research In Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN), also published in 2018, urge clinicians and patients to consider the possibility of resumed disease activity or even rebound. There are limited data to support decision-making when it comes to discontinuing DMT, but randomized controlled trials are underway. Some studies have shown that when patients go off DMT, those most likely to experience recurrence are relatively younger, have had recent disease activity clinically with a relapse, and have had a recent active lesion on their scan.
Learn more about DMT for MS.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kerstin Hellwig, Christopher Luzzio. Fast Five Quiz: Treatment in Relapsed Multiple Sclerosis - Medscape - Nov 22, 2022.